Dianthus director exercises options and sells shares

Dianthus Therapeutics, Inc. director Anne McGeorge reported option exercises and related sales of common stock.

Rhea-AI Filing Summary

Dianthus Therapeutics, Inc. director Anne McGeorge reported option exercises and related sales of common stock. On August 10, 2026, she exercised options for 7,750 shares of common stock at exercise prices of $19.36 and $11.20 per share, then sold 7,750 shares in multiple transactions at weighted average prices between $106.79 and $111.63 per share. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026.

Insider Trade Summary 10b5-1

Exercise and Sale: 7,750 shares ($748K approx. pre-tax spread)

Exercise and Sale 9 txns

Insider McGeorge Anne

Role Director

Sold 7,750 shs ($845K)

Approx. gross sale proceeds $845K

Approx. exercise cost $97K

Approx. pre-tax spread $748K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F1	1,250	$0.00	$0.00
Exercise	Stock Option (Right to Buy) F1	6,500	$0.00	$0.00
Exercise	Common Stock F1	1,250	$19.36	$24K
Exercise	Common Stock F1	6,500	$11.20	$73K
Sale	Common Stock F1, F2	1,450	$107.58	$156K
Sale	Common Stock F1, F3	2,800	$108.38	$303K
Sale	Common Stock F1, F4	1,800	$109.30	$197K
Sale	Common Stock F1, F5	1,000	$110.64	$111K
Sale	Common Stock F1, F6	700	$111.41	$78K

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 0 shares (Direct)

Footnotes (6)

1. F1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026.
2. F2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $106.79 to $107.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
3. F3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.84 to $108.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
4. F4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $108.89 to $109.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
5. F5. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $110.05 to $111.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
6. F6. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $111.15 to $111.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

Key Figures

Options exercised: 7,750 shares Exercise prices: $19.36 and $11.20 per share Shares sold: 7,750 shares +3 more

6 metrics

Options exercised 7,750 shares Total shares underlying options exercised on August 10, 2026

Exercise prices $19.36 and $11.20 per share Stock option exercise prices for 1,250 and 6,500 shares, respectively

Shares sold 7,750 shares Total common shares sold in multiple transactions on August 10, 2026

Weighted average sale prices $107.58–$111.41 per share Per reported sale rows; detailed ranges from $106.79 to $111.63

10b5-1 plan adoption date May 11, 2026 Rule 10b5-1 trading plan governing the reported transactions

Option expiration dates June 27, 2032 and September 10, 2033 Expiration of options originally exercisable in 2023 and 2024

Key Terms

Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), derivative security, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported above is a weighted average price. The shares were sold"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

open market or private transaction financial

"transaction_code_description": "Sale in open market or private transaction""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did DNTH director Anne McGeorge report in this Form 4?

Anne McGeorge reported exercising stock options for 7,750 shares of Dianthus Therapeutics common stock and selling 7,750 shares in market transactions on August 10, 2026, under a pre-arranged Rule 10b5-1 trading plan.

How many Dianthus Therapeutics (DNTH) options did Anne McGeorge exercise?

She exercised options covering 7,750 shares of Dianthus Therapeutics common stock. The options had exercise prices of $19.36 and $11.20 per share, originally exercisable on June 28, 2023, and May 23, 2024, respectively.

How many DNTH shares did Anne McGeorge sell and at what prices?

She sold 7,750 shares of Dianthus Therapeutics common stock in several trades at weighted average prices from $107.58 to $111.41 per share, with footnotes detailing price ranges from $106.79 up to $111.63.

Were Anne McGeorge’s DNTH trades under a Rule 10b5-1 plan?

Yes. A footnote states the transactions were effected under a Rule 10b5-1 trading plan adopted on May 11, 2026, indicating the trades followed a pre-established schedule rather than discretionary timing.

What types of securities are involved in Anne McGeorge’s DNTH Form 4?

The filing reports transactions in stock options (right to buy) and common stock. Options were exercised to acquire 7,750 common shares, and the same number of common shares were then sold in market transactions on August 10, 2026.

Does the Form 4 show Anne McGeorge’s remaining DNTH holdings?

The structured data lists the reported transactions but does not provide a specific figure for shares owned after these trades. Only the exercised option amounts and the corresponding share sales on August 10, 2026 are detailed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/11/2026 - 05:15 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McGeorge Anne

(Last) (First) (Middle)

C/O DIANTHUS THERAPEUTICS, INC.

7 TIMES SQUARE, 43RD FLOOR

(Street)

NEW YORK NEW YORK 10036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Dianthus Therapeutics, Inc. /DE/ [ DNTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/10/2026		M(1)		1,250	A	$19.36	1,250	D
Common Stock	08/10/2026		M(1)		6,500	A	$11.2	7,750	D
Common Stock	08/10/2026		S(1)		1,450	D	$107.58(2)	6,300	D
Common Stock	08/10/2026		S(1)		2,800	D	$108.38(3)	3,500	D
Common Stock	08/10/2026		S(1)		1,800	D	$109.3(4)	1,700	D
Common Stock	08/10/2026		S(1)		1,000	D	$110.64(5)	700	D
Common Stock	08/10/2026		S(1)		700	D	$111.41(6)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$19.36	08/10/2026		M(1)			1,250	06/28/2023	06/27/2032	Common Stock	1,250	$0	0	D
Stock Option (Right to Buy)	$11.2	08/10/2026		M(1)			6,500	05/23/2024	09/10/2033	Common Stock	6,500	$0	0	D

Explanation of Responses:

1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026.

2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $106.79 to $107.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.84 to $108.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $108.89 to $109.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

5. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $110.05 to $111.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

6. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $111.15 to $111.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

	/s/ Adam Veness, as attorney-in-fact for Anne McGeorge	08/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)